Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: A systematic review and meta-analysis

Virology Journal

Volumn 8, Issue , 2011, Pages

  Sheng, Yun Jian ^a   Liu, Jun Ying ^a   Tong, Shi Wen ^a   Hu, Huai Dong ^a   Zhang, Da Zhi ^a   Hu, Peng ^a   Ren, Hong ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Adefovir; Chronic Hepatitis B; Combination therapy; Entecavir; Lamivudine; Resistance

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; CREATININE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA; ADENINE; ANTIVIRUS AGENT; DRUG DERIVATIVE; GUANINE; PHOSPHONIC ACID DERIVATIVE;

ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; CHRONIC HEPATITIS; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; KIDNEY FUNCTION; LIVER FUNCTION; META ANALYSIS; MONOTHERAPY; NAUSEA; PREDICTION; REVIEW; SEROCONVERSION; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT FAILURE; TREATMENT RESPONSE; VIRUS HEPATITIS; VIRUS MUTATION; VIRUS RESISTANCE; ANTIVIRAL RESISTANCE; COMPARATIVE STUDY; DRUG COMBINATION; LIVER FUNCTION TEST; METHODOLOGY; SALVAGE THERAPY; TIME; TREATMENT OUTCOME; VIRUS LOAD;

HEPATITIS B VIRUS;

ADENINE; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GUANINE; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LIVER FUNCTION TESTS; PHOSPHONIC ACIDS; SALVAGE THERAPY; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 79961120304     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-8-393     Document Type: Review

References (43)

1. Clinical relevance and public health significance of hepatitis B virus genomic variations. Cao GW, World J Gastroenterol 2009 15 46 5761 5769 10.3748/wjg.15.5761 19998495
2. Hepatitis B virus infection - natural history and clinical consequences. Ganem D, Prince AM, N Engl J Med 2004 350 11 1118 1129 10.1056/NEJMra031087 15014185 (Pubitemid 38298992)
3. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH, JAMA 2006 295 1 65 73 10.1001/jama.295.1.65 16391218 (Pubitemid 43042691)
4. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ, Gastroenterology 2006 130 3 678 686 10.1053/j.gastro.2005.11.016 16530509 (Pubitemid 43374518)
5. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Pawlotsky JM, Dusheiko G, Hatzakis A, Lau D, Lau G, Liang TJ, Locarnini S, Martin P, Richman DD, Zoulim F, Gastroenterology 2008 134 2 405 415 10.1053/j.gastro.2007.11.036 18242209 (Pubitemid 351181309)
6. Long-Term Nucleos(t)ide Analogues Therapy for Adults With Chronic Hepatitis B reduces the Risk of Long-Term Complications: a meta-analysis. Zhang QQ, An X, Liu YH, Li SY, Zhong Q, Wang J, Hu HD, Zhang DZ, Ren H, Hu P, Virol J 2011 8 72 10.1186/1743-422X-8-72 21324130
7. Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis. Yang YF, Zhao W, Zhong YD, Xia HM, Shen L, Zhang N, J Viral Hepat 2009 16 4 265 271 10.1111/j.1365-2893.2009.01070.x 19220736
8. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, Brown N, Woessner M, Boehme R, Condreay L, Clin Infect Dis 2003 36 6 687 696 10.1086/368083 12627352 (Pubitemid 36337972)
9. Chronic hepatitis B. Lok AS, McMahon BJ, Hepatology 2007 45 2 507 539 10.1002/hep.21513 17256718 (Pubitemid 46374607)
10. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Ma J, Brosgart CL, Borroto-Esoda K, Arterburn S, Chuck SL, Gastroenterology 2006 131 6 1743 1751 10.1053/j.gastro.2006.09.020 17087951 (Pubitemid 44958517)
11. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Marcellin P, Chang TT, Lim SG, Sievert W, Tong M, Arterburn S, Borroto-Esoda K, Frederick D, Rousseau F, Hepatology 2008 48 3 750 758 10.1002/hep.22414 18752330
12. Lamivudine-resistant chronic hepatitis B: an observational study on adefovir in monotherapy or in combination with lamivudine. Gaia S, Barbon V, Smedile A, Olivero A, Carenzi S, Lagget M, Alessandria C, Rizzetto M, Marzano A, J Hepatol 2008 48 4 540 547 10.1016/j.jhep.2007.12.018 18279995
13. Meta-analysis: adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus. Chen EQ, Wang LC, Lei J, Xu L, Tang H, Virol J 2009 6 163 10.1186/1743-422X-6-163 19818142
14. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, DeHertogh D, Wilber R, Zink RC, Cross A, Colonno R, Fernandes L, N Engl J Med 2006 354 10 1011 1020 10.1056/NEJMoa051287 16525138 (Pubitemid 43357805)
15. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J, Han KH, Chao YC, Lee SD, Harris M, Yang J, Colonno R, Brett-Smith H, Gastroenterology 2007 133 5 1437 1444 10.1053/j.gastro.2007.08.025 17983800 (Pubitemid 350029745)
16. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir. Leung N, Peng CY, Hann HW, Sollano J, Lao-Tan J, Hsu CW, Lesmana L, Yuen MF, Jeffers L, Sherman M, Min A, Mencarini K, Diva U, Cross A, Wilber R, Lopez-Talavera J, Hepatology 2009 49 1 72 79 10.1002/hep.22658 19065670
17. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, Wichroski MJ, Xu D, Yang J, Wilber RB, Colonno RJ, Hepatology 2009 49 5 1503 1514 10.1002/hep.22841 19280622
18. Chronic hepatitis B: update 2009. Lok AS, McMahon BJ, Hepatology 2009 50 3 661 662 10.1002/hep.23190 19714720
19. EASL Clinical Practice Guidelines. Pawlotsky JM, J Hepatol 2009 50 2 243. 10.1016/j.jhep.2008.11.012 19081157
20. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ, Control Clin Trials 1996 17 1 1 12 10.1016/0197-2456(95) 00134-4 8721797 (Pubitemid 26120810)
21. Add-On Adefovir Is Superior to a Switch to Entecavir as Rescue Therapy for Lamivudine-Resistant Chronic Hepatitis B. Chung GE, Kim W, Lee KL, Hwang SY, Lee JH, Kim HY, Jung YJ, Kim D, Jeong JB, Kim BG, Kim YJ, Yoon JH, Lee HS, Dig Dis Sci 2011 Jul 56 7 2130 2136 10.1007/s10620-010-1561-2 21253834
22. Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B. Ryu HJ, Lee JM, Ahn SH, Kim do Y, Lee MH, Han KH, Chon CY, Park JY, J Med Virol 2010 82 11 1835 1842 10.1002/jmv.21898 20872709
23. [A study on the treatment of chronic hepatitis B with YMDD mutation]. Qiu YW, Jiang XH, Huang LH, Hu TH, Ding H, Jiang YM, Dai YX, Zhou M, Zhonghua Gan Zang Bing Za Zhi 2009 17 3 171 174 19335977
24. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy. Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI, J Gastroenterol Hepatol 2010 25 8 1374 1380 10.1111/j.1440-1746. 2010.06381.x 20659226
25. Entecavir therapy for Lamivudine resistant HBV cirrhotic patients waiting for olt: Viral and biochemical outcomes at one year. Pellicelli AM, Barbarini G, Romano M, Furlan C, Paffetti A, Villani R, D'Ambrosio C, Guarascio P, Cerasari G, Fondacaro L, Mazzoni E, Barlattani A, Mecenate F, Nosotti L, Puoti C, Morrone A, Gentilucci UV, Picardi A, Lusi AE, Andreoli A, Soccorsi F, Hepatology 2009 50 SUPPL.4 514A
26. Entecavir rescue therapy versus adefovir combination therapy in lamivudine-refractory patients with chronic hepatitis B. Lee HW, Kim HJ, Choi CH, Do JH, Chang SK, Hepatology International 2010 4 1 132 133
27. Adding adefovir compared with switching to entecavir in paients with lamivudine-resistant chonic heaptitis B (ACE STUDY)-a multicenter prospective randomized study: one-year interim analysis. Yim HJ, Seo YS, Kim JH, Kim CW, Lee CD, Park SH, Lee MS, Park CKN, Chae HB, Kim MY, Baik SK, Kim YS, Kim JH, Il Lee J, Um SH, Hepatology 2010 52 SUPPL.4 560A
28. The comparison of three rescue treatment strategies for lamivudine-resistant chronic hepatitis B: lamivudine and adefovir combination therap, entecavir monotherapy, and adefovir monotherapy. Jang E, Lee J, Yoon J, Cho E, Yang H, Kwak M, Ahn D, Hwang S, Yu S, Lee C, Kim Y, Lee H, Hepatology 2010 52 SUPPL 4 520A
29. Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy. Liaw YF, Antivir Ther 2006 11 6 669 679 17310811
30. Antiviral resistance and hepatitis B therapy. Ghany MG, Doo EC, Hepatology 2009 49 5 Suppl 174 184 19399794
31. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Sherman M, Yurdaydin C, Simsek H, Silva M, Liaw YF, Rustgi VK, Sette H, Tsai N, Tenney DJ, Vaughan J, Kreter B, Hindes R, Hepatology 2008 48 1 99 108 10.1002/hep.22323 18537189 (Pubitemid 351975535)
32. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients. Suzuki F, Toyoda J, Katano Y, Sata M, Moriyama M, Imazeki F, Kage M, Seriu T, Omata M, Kumada H, J Gastroenterol Hepatol 2008 23 9 1320 1326 10.1111/j.1440-1746.2008. 05455.x 18554238
33. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Tenney DJ, Levine SM, Rose RE, Walsh AW, Weinheimer SP, Discotto L, Plym M, Pokornowski K, Yu CF, Angus P, Ayres A, Bartholomeusz A, Sievert W, Thompson G, Warner N, Locarnini S, Colonno RJ, Antimicrob Agents Chemother 2004 48 9 3498 3507 10.1128/AAC.48.9.3498-3507.2004 15328117 (Pubitemid 39129351)
34. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. Villet S, Ollivet A, Pichoud C, Barraud L, Villeneuve JP, Trepo C, Zoulim F, J Hepatol 2007 46 3 531 538 10.1016/j.jhep.2006.11.016 17239478 (Pubitemid 46201724)
35. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon E, Colombo M, Gastroenterology 2007 133 5 1445 1451 10.1053/j.gastro.2007.08.079 17983801 (Pubitemid 350047463)
36. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ, Hepatology 2007 45 2 307 313 10.1002/hep.21534 17256746 (Pubitemid 46374587)
37. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up. Yatsuji H, Suzuki F, Sezaki H, Akuta N, Suzuki Y, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Watahiki S, Iwasaki S, Kumada H, J Hepatol 2008 48 6 923 931 10.1016/j.jhep.2008.02.019 18433925
38. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir. Heo NY, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ, J Hepatol 2010 53 3 449 454 10.1016/j.jhep.2010.03.020 20646776
39. Comparision of entecavir (ETV) monotherapy and lamivudine (LAM) plus adefovir (ADV) in patients with chronic hepatitis B who have sequentially failed with LAM and ADV. Ryu H, Lee JM, Ahn SH, Kim DY, Lee KS, Han K-H, Chon CY, Moon YM, Park JY, Hepatology International 2010 4 1 1(165)
40. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. Villet S, Pichoud C, Billioud G, Barraud L, Durantel S, Trepo C, Zoulim F, J Hepatol 2008 48 5 747 755 10.1016/j.jhep.2008.01.027 18331765
41. Unusual selection of rtA181V HBV mutants cross-resistant to adefovir following prolonged lamivudine monotherapy: report of two cases. Gerolami R, Bourliere M, Colson P, Halfon P, Borentain P, Henry M, Botta D, Thibault V, Khiri H, Tamalet C, Antivir Ther 2006 11 8 1103 1106 17302381 (Pubitemid 44955187)
42. Complex dynamics of hepatitis B virus resistance to adefovir. Pallier C, Rodriguez C, Brillet R, Nordmann P, Hezode C, Pawlotsky JM, Hepatology 2009 49 1 50 59 10.1002/hep.22634 19065672
43. High risk of renal impairment during long-term adefovir and lamivudine combination therapy in patients with lamivudine-resistant chronic hepatitis B. Vigano M, Lampertico P, Iavarone M, J Hepatol 2009 50 338 339